MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100665 | Name: Nedaplatin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy. It produces less nausea, vomiting and nephrotoxicity than other platinum-containing drugs. (Source: http://en.wikipedia.org/wiki/Nedaplatin).

Chemical Structure

Nedaplatin
Nedaplatin
CAS#95734-82-0

Theoretical Analysis

MedKoo Cat#: 100665

Name: Nedaplatin

CAS#: 95734-82-0

Chemical Formula: C2H6N2O3Pt

Exact Mass: 303.0183

Molecular Weight: 301.16

Elemental Analysis: C, 7.98; H, 2.01; N, 9.30; O, 15.94; Pt, 64.78

Price and Availability

Size Price Availability Quantity
10mg USD 310.00
25mg USD 600.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
IUPAC/Chemical Name
platinum, diammine(hydroxy-kappaO)acetato(2-)-kappaO)-, (SP-4-3)-
InChi Key
KLNFSAOEKUDMFA-UHFFFAOYSA-N
InChi Code
InChI=1S/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2
SMILES Code
O=C([O-])CO.[NH2-].[NH2-].[Pt+2]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Nedaplatin is a second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.
In vitro activity:
This study shows that by encapsulating nedaplatin in PEGylated liposomes, the platinum uptake cytotoxicity and genotoxicity of nedaplatin was significantly enhanced in both cancer cell lines. Moreover, the enhanced platinum uptake as well as the cytotoxic/antiproliferative effect of liposomal nedaplatin appears to be selective to cancer cells as it was not observed on two noncancer cell lines. Reference: Pharmaceutics. 2020 Sep 10;12(9):863. https://pubmed.ncbi.nlm.nih.gov/32927897/
In vivo activity:
A fixed 5-FU dose was injected daily for 5 days and increasing doses of either NDP (nedaplatin) or CDDP were injected once via the tail vein into the Lewis lung carcinoma-implanted mice. The sequential administration of either NDP or CDDP prior to 5-FU (NF or CF therapy) resulted in severe body weight loss followed by the death of the tumour-bearing mice when the high-dose of NDP or CDDP was administered. In contrast, the sequential administration of 5-FU prior to NDP or CDDP (FN or FC therapy) resulted in synergistically enhanced inhibition of tumour growth and prolonged survival in comparison with NDP, CDDP or 5-FU monotherapy. Reference: Eur J Cancer. 1998 Oct;34(11):1796-801. https://pubmed.ncbi.nlm.nih.gov/9893671/
Solvent mg/mL mM
Solubility
DMF 1.0 3.30
Water 13.6 45.16
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 301.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. El-Shafie S, Fahmy SA, Ziko L, Elzahed N, Shoeib T, Kakarougkas A. Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells. Pharmaceutics. 2020 Sep 10;12(9):863. doi: 10.3390/pharmaceutics12090863. PMID: 32927897; PMCID: PMC7559812. 2. Jing C, Wang Z, Lou R, Wu J, Shi C, Chen D, Ma R, Liu S, Cao H, Feng J. Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH. J Cancer. 2020 Jan 1;11(3):559-569. doi: 10.7150/jca.35792. PMID: 31942179; PMCID: PMC6959054. 3. Matsumoto M, Takeda Y, Maki H, Hojo K, Wada T, Nishitani Y, Maekawa R, Yoshioka T. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res. 2001 Jan;92(1):51-8. doi: 10.1111/j.1349-7006.2001.tb01047.x. PMID: 11173544; PMCID: PMC5926590. 4. Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K, Yoshioka T. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer. 1998 Oct;34(11):1796-801. doi: 10.1016/s0959-8049(98)00194-4. PMID: 9893671.
In vitro protocol:
1. El-Shafie S, Fahmy SA, Ziko L, Elzahed N, Shoeib T, Kakarougkas A. Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells. Pharmaceutics. 2020 Sep 10;12(9):863. doi: 10.3390/pharmaceutics12090863. PMID: 32927897; PMCID: PMC7559812. 2. Jing C, Wang Z, Lou R, Wu J, Shi C, Chen D, Ma R, Liu S, Cao H, Feng J. Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH. J Cancer. 2020 Jan 1;11(3):559-569. doi: 10.7150/jca.35792. PMID: 31942179; PMCID: PMC6959054.
In vivo protocol:
1. Matsumoto M, Takeda Y, Maki H, Hojo K, Wada T, Nishitani Y, Maekawa R, Yoshioka T. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res. 2001 Jan;92(1):51-8. doi: 10.1111/j.1349-7006.2001.tb01047.x. PMID: 11173544; PMCID: PMC5926590. 2. Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K, Yoshioka T. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer. 1998 Oct;34(11):1796-801. doi: 10.1016/s0959-8049(98)00194-4. PMID: 9893671.
1: Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20593091. 2: Miura T, Hosojima Y, Nakamura J, Yamada S, Nakazawa Y, Ozeki Y, Miura T, Yanagi M, Yamazaki H, Takahashi T. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance]. Gan To Kagaku Ryoho. 2010 May;37(5):883-5. Japanese. PubMed PMID: 20495320. 3: Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, Zhang Y. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2010 May 1;10(4):272-82. PubMed PMID: 20184553. 4: Iijima S, Makari Y, Kato T, Ooshima S, Hoshi M, Doi T, Miyake Y, Sakamoto T, Kato A, Miyo M, Kurokawa E, Kikkawa N. [A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2052-4. Japanese. PubMed PMID: 20037320. 5: Zhang J, Liu D, Li Y, Sun J, Wang L, Zang A. Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem. 2009 Oct;9(11):1357-66. Review. PubMed PMID: 19929810. 6: Alberto ME, Lucas MF, Pavelka M, Russo N. The second-generation anticancer drug Nedaplatin: a theoretical investigation on the hydrolysis mechanism. J Phys Chem B. 2009 Oct 29;113(43):14473-9. PubMed PMID: 19778071. 7: Nishime C, Ohnishi Y, Suemizu H, Tamaoki N, Kusumi T, Sato F, Yamazaki H, Nakamura M, Ueyama Y, Kijima H. In vivo chemotherapeutic profile of human gallbladder small cell carcinoma. Biomed Res. 2008 Oct;29(5):251-6. PubMed PMID: 18997440. 8: Tanaka T, Yukawa K, Umesaki N. Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 2007;28(5):352-5. PubMed PMID: 17966212. 9: Loh GW, Ting LS, Ensom MH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet. 2007;46(6):471-94. Review. PubMed PMID: 17518507. 10: Xu RH, Shi YX, Guan ZZ, Jiang WQ, Huang H, Ma ZY, Wang JH, Hu XH, Xie WM, Li XG, Liu YL, Pan LX, Dai AD, Zhuang W, Zhang C. [Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma]. Ai Zheng. 2006 Dec;25(12):1565-8. Chinese. PubMed PMID: 17166388.

View History

Nelonemdaz potassium

Nelonemdaz potassium